McKesson
One Post Street
San Francisco
California
94104
United States
Tel: 415-983-8982
Fax: 415-983-8900
Website: http://www.mckesson.com/
377 articles about McKesson
-
McKesson and Aetion Collaborate to Advance Cancer Research With Real-World Data
10/15/2019
Relationship pairs Aetion Evidence PlatformTM and McKesson’s robust oncology data sets to accelerate regulatory-grade oncology studies
-
McKesson and TrakCel Launch Innovative Collaboration to Support Commercialization of Cell and Gene Therapies
9/11/2019
Goal is to increase access to complex medications to ensure patients get the right drug at the right time faster
-
ROZLYTREK™ (entrectinib), FDA Approved for Hard-to-Treat NTRK Fusion-Positive Tumors, Available at Biologics by McKesson
8/21/2019
ROZLYTREK, approved by the FDA on August 15, 2019, is an oral therapy for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer
-
McKesson Playing Pivotal Role in Phase II of Friends of Cancer Research Real-World Evidence Initiative
8/8/2019
Pivotal study to inform framework for how to use RWE to support regulatory and reimbursement decisions
-
TURALIO™ (pexidartinib), FDA Approved Treatment of TGCT, Available at Biologics by McKesson
8/7/2019
Exclusive distribution agreement with Daiichi Sankyo, Inc. expands rare disease and complex therapeutic specialty pharmacy needs
-
McKesson Reports Fiscal 2020 First-Quarter Results
7/31/2019
McKesson Corporation reported that revenues for the first quarter ended June 30, 2019, were $55.7 billion compared to $52.6 billion a year ago, an increase of 6% on a reported basis and an increase of 7% on an FX-adjusted basis.
-
McKesson Opens New Distribution Center in Seattle Area
7/25/2019
Eco-friendly facility features latest automation and supply chain technology
-
CORRECTING and REPLACING McKesson Reports Fiscal 2019 Fourth-Quarter and Full-Year Results
5/8/2019
McKesson Corporation reported that revenues for the fourth quarter ended March 31, 2019, were $52.4 billion compared to $51.6 billion a year ago, an increase of 2% on a reported basis and an increase of 3% on an FX-adjusted basis.
-
McKesson Reports Fiscal 2019 Fourth-Quarter and Full-Year Results
5/8/2019
Fourth-quarter fiscal 2019 revenues of $52.4 billion and full-year fiscal 2019 revenues of $214.3 billion, a full-year increase of 3%.
-
McKesson Appoints Tracy Faber to Top HR Role
4/26/2019
McKesson Corporation announced that Tracy Faber has been appointed executive vice president and chief human resources officer (CHRO), effective October 1, 2019. Faber will report to CEO Brian Tyler.
-
Kirk Kaminsky to Lead McKesson’s U.S.-Based Pharmaceutical Business
4/15/2019
McKesson Corporation announced that Kirk Kaminsky will be the new president of McKesson’s U.S. Pharmaceutical and Specialty Solutions business.
-
McKesson Corporation to Hold Fiscal 2019 Fourth Quarter Conference Call and Participate in the Bank of America Merrill Lynch Health Care Conference
4/10/2019
McKesson Corporation will release financial results for its fourth quarter ended March 31, 2019 on Wednesday, May 8, 2019, prior to the opening of trading on the New York Stock Exchange.
-
Brian Tyler Becomes McKesson’s New CEO
4/1/2019
Edward Mueller assumes role as independent chair of McKesson’s Board of Directors
-
McKesson ideaShare Unites Independent Pharmacy
3/26/2019
Premier community pharmacy education and networking event hits Orlando in 2019
-
The FDA issues Warning Letters to biopharma, medical device and food companies when they find that a manufacturer has significantly violated FDA regulations. As of March 4, the agency issued 45 Warning Letters this year.
-
During his two years in office, former Texas Secretary of State Rolando Pablos flexed the muscles of his office to make recruiting biotech and pharma companies a priority.
-
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
-
Global Health Care Leaders Back Aetion with $27 Million Strategic Investment
2/5/2019
Sanofi, UCB, McKesson Ventures, and Horizon Health Services Endorse Aetion's Vision for Real-World Evidence
-
McKesson Reports Fiscal 2019 Third-Quarter Results
1/31/2019
Revenues of $56.2 billion for the third quarter, up 5% year over year.
-
McKesson Joins World Cancer Day Efforts
1/29/2019
Company Using Technology and Resources to Advance Cancer Care, Connecting Patients to Latest Therapies and Clinical Trials and Investing in Ways to Predict Cancer Earlier